Auscann Group Holdings Ltd (ASX: AC8) Share Price and News

Auscann Group Holdings Ltd (ASX: AC8) is a pharmaceutical company based in Western Australia. Its focus is on developing, producing and distributing a range of cannabinoid treatments for use in Australia and internationally.

According to Auscann, the company’s products are the result of a stringent development program that aims to produce stable and effective cannabinoid-based medicines. Auscann also seeks to generate clinical evidence supporting the efficacy of its products to support further market penetration.

Whilst working directly with patients, Auscann’s primary focus is on providing healthcare professionals with optimal treatment solutions to help them better care for their patients. The company also provides healthcare professionals with the tools to personalise and adjust dosage and treatment programs for each individual.

AusCann was readmitted to the ASX in early 2017 after it was acquired by the already listed company TW Holdings Limited. In the months following, the Auscann share price surged by nearly 200%. Within 12 months, the Auscann share price had gone on to deliver growth of nearly 500% over its ASX readmittance value. Since then however, the Auscann share price has trended lower and has not traded over $1 since late 2018.